资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.

Retrovirology. 2016;

SalehSuha，LuHao K，EvansVanessa，HarissonDavid，ZhouJingling，JaworowskiAnthony，SallmannGeorgina，CheongKarey Y，MotaTalia M，TennakoonSurekha，AngelovichThomas A，AndersonJenny，HarmanAndrew，CunninghamAnthony，GrayLachlan，ChurchillMelissa，MakJohnson，DrummerHeidi，VatakisDimitrios N，LewinSharon R，CameronPa

Products/Services Used	Details	Operation
Proteins, Expression, Isolation and Analysis	Primary antibodies to Pin1 (Santa Cruz Biotechnology Inc, Dallas, TX) was added and incubated overnight at 4 °C followed by the addition of protein-G-sephrose beads (Genscript, Piscataway, NJ) for another 3 h.	Get A Quote

摘要

Eradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the persistence of long-lived latently infected resting memory CD4(+) T cells. We previously reported that HIV latency could be established in resting CD4(+) T cells in the presence of the chemokine CCL19. To define how CCL19 facilitated the establishment of latent HIV infection， the role of chemokine receptor signalling was explored.